WXXWY Stock Performance, Insider Transaction and News

WXXWY - WUXI BIOLOGICS (CAYMAN) INC UNS

Market Cap	23.67B	P/E	38.48	EPS this Y	-	Ern Qtrly Grth	-33.90%
Income	2.63B	Forward P/E	-	EPS next Y	-	50D Avg Chg	6.00%
Sales	17.12B	PEG	-	EPS past 5Y	-	200D Avg Chg	-13.00%
Dividend	N/A	Price/Book	0.67	EPS next 5Y	-	52W High Chg	-42.00%
Recommedations	-	Quick Ratio	2.40	Shares Outstanding	2.05B	52W Low Chg	28.00%
Insider Own	-	ROA	3.98%	Shares Float	3.55B	Beta	0.62
Inst Own	0.00%	ROE	7.20%	Shares Shorted/Prior	-/-	Price	11.16
Gross Margin	38.66%	Profit Margin	15.38%	Avg. Volume	93,132	Target Price	-
Oper. Margin	21.22%	Earnings Date	Aug 21	Volume	193,150	Change	-2.02%

Healthcare | Biotechnology | China

About WUXI BIOLOGICS (CAYMAN) INC UNS

WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People's Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstream process development through its contract research, development, and manufacturing organization platforms, including WuXiBody, SDArBodY, T cell engager, Single B Cell Cloning Technology, WuXia, WuXiUP, WuXiUI, and WuXiHigh. It also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, production and sales of medicals, and biologics clinical and manufacturing services; production and sale of medicals; vaccine contract development and manufacturing organization (CDMO) and related business; and engages in investment and material supplier activities. The company has a research service agreement with BioNTech SE to discover and investigate monoclonal antibodies for developing next-generation therapeutic product candidates. The company was incorporated in 2014 and is headquartered in Wuxi, China.

WUXI BIOLOGICS (CAYMAN) INC UNS News

12/12/24	WuXi Biologics Included in UNGC 20 Case Examples of Sustainable Development for 20 Years Collection
12/05/24	WuXi Biologics Achieves Major Milestones at Ireland Site with Multiple 16,000L PPQ Success and HPRA GMP Authorizations
11/13/24	WuXi Biologics Germany to Enhance Capabilities with New Prefilled Syringes Line
10/28/24	WuXi Biologics Launches WuXia™ RidGS for Non-Antibiotic Cell Line Development
10/16/24	WuXi Biologics Receives ESG Corporate Platinum Award from The Asset for Fourth Consecutive Year
10/09/24	WuXi Biologics (Cayman) Inc (WXXWY) Half Year 2024 Earnings Call Highlights: Navigating Growth ...
10/04/24	WuXi AppTec, WuXi Biologics surge in Hong Kong as biotech firms put some operations for sale
09/23/24	WuXi Biologics Included in Hang Seng ESG 50 Index
08/30/24	WuXi Biologics Successfully Completes First Scale-Up of High-Productivity Bioprocessing Platform WuXiUI™ in 2,000L GMP Manufacturing
08/21/24	WuXi Biologics Reports Solid 2024 Interim Results
08/09/24	WuXi Biologics and Medigene link on T cell engagers for cancer
08/08/24	WuXi Biologics and Medigene Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers
08/01/24	WuXi Biologics' Four Manufacturing Facilities and Biosafety Testing Center Certified Again by European Medicines Agency for Ten Biologics
07/10/24	WuXi Biologics Named Constituent of the FTSE4Good Index Series for Fourth Year
05/16/24	US House committee moves quickly to approve bill limiting business with Chinese biotech firms
04/29/24	WuXi Biologics Releases 2023 ESG Report Demonstrating Strong Sustainability Commitment
04/25/24	AstraZeneca CEO on US-China tensions: 'We have established a very resilient supply chain'
03/26/24	WuXi Biologics Reports Solid 2023 Annual Results
03/22/24	WuXi Biologics Named to CDP 'A List' for Water Security
03/05/24	WuXi Biologics Achieves Leadership Level in 2023 CDP Climate Change Assessment

WXXWY Chatroom

Polis58 Posted - 11/29/24

$WXXWY

Polis58 Posted - 11/29/24

$WXXWY Wuxi view on BIOSECURE Act

Polis58 Posted - 11/29/24

$WXXWY https://www.wuxibiologics.com/locations-facilities/ Global presence (including USA)

NoRisksNoFun Posted - 2 months ago

$WXXWY $xbi $holo $VKTX who knows anything about wuxi???ty for Info

Anonymous92 Posted - 4 months ago

$WXXWY currently no Position. What are your thoughts on the recent ER?

TalkMarkets Posted - 4 months ago

Week In Review: Curon Out-Licenses T-Cell-Engager To Merck For $700 Million Upfront $DSKYF $HARP $WXXWY https://talkmarkets.com/content/global-markets/week-in-review-curon-out-licenses-t-cell-engager-to-merck-for-700-million-upfront?post=457831

jParkz Posted - 5 months ago

$WXXWY News WuXi Biologics Named Constituent of the FTSE4Good Index Series for Fourth Year https://marketwirenews.com/news-releases/wuxi-biologics-named-constituent-of-the-ftse4good-in-5230306323113555.html $WXXWY

ridhwan1820 Posted - 5 months ago

$WXXWY added more here

XBI2022 Posted - 6 months ago

$WXXWY

ridhwan1820 Posted - 6 months ago

$WXXWY this is a PROFITABLE business. Sure its revenues growth is not as impressive as in the past, but you need to understand the biotech sector is highly cyclical. And i dont think the bill will ever be passed. Its just a negotiating chip the US intends to use with china. I bought so much a month ago and yesterday. Im up 12% but i am not selling. I see this at $12 minimum in the next couple of years

XBI2022 Posted - 6 months ago

$WXXWY Reuters China's WuXi Biologics hits near 3-week peak after shares buyback 12 jun 2024, kl 4:06 fm GMT ** Shares of Chinese contract drug research and development group WuXi Biologics 2269.HK jump 17.7% to HK$12.92, highest since May 24 ** Stock last up 16.2%, on track for biggest one-day pct rise since November 2022; biggest pct gainer in the Hang Seng Composite Index .HSCI ** Co repurchased 1.81 mln shares in open market on Tuesday at a price between HK$10.98 and HK$11.08 per share for an aggregate HK$19.92 mln ($2.55 mln), a Hong Kong stock exchange filing showed ** Hong Kong's healthcare index .HSCIH rises 1.2%, while the Hang Seng Composite Index .HSCI falls 1.3% and the Hang Seng Index .HSI drops 1.5% ** Stock down 57.2% YTD ($1 = 7.8088 Hong Kong dollars)

ridhwan1820 Posted - 6 months ago

$WXXWY https://finance.yahoo.com/news/wuxi-biologics-jumps-hope-key-071236493.html

ridhwan1820 Posted - 05/30/24

$WXXWY is there nobody having interest in this?

Anonymous92 Posted - 9 months ago

$WXXWY bought in again today

Coolidge87 Posted - 9 months ago

$WXXWY High risk, but decided to open a small position here.

bluffmeariver Posted - 9 months ago

$WXXWY Looking to start the position

JohnTill Posted - 9 months ago

$WXXWY yikes - timed that exit well and know better to stay around when regulators have a hate on for a sector/company.

JohnTill Posted - 9 months ago

$WXXWY Out for the last of the position today at $5.27. Only a 33% profit overall on the play but given the dual risks now I am going to step aside for greener pastures. It will likely get cleared now and rocket now that I have sold but all about risk-reward. Good luck to those still long.

JohnTill Posted - 9 months ago

$WXXWY Been a nice ride - locked in KURE today on the underside touch of the 20MA and also sold a few more WXXWY at $4.80 for some decent profits. China is running and I will likely regret locking in so much but with US elections around the corner I do not want to risk a biotech surprise like the two already in play. I would rather raise a little money now while it is sunny and let the profits run. Good luck to those long.